ESR2 and neoplasm: The phenotyping of the latest mouse model with the crispr-cas9-mediated knockout of ERβ reports a tumor suppressor function in the ventral prostate and mammary epithelium, where the loss of the receptor leads to increased activity of the androgen receptor (AR) and ERα, respectively [18].